entertainment -WSS

entertainment

author：fashion 2025-09-03 03:28:15 - browse：2934

Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner would step down from its board, sending a signal to investors that the company’s fractious recent history might be coming to a close.

What Biogen didn’t disclose is that its nominee to replace Denner on the board, Susan Langer, is Denner’s live-in romantic partner and the mother of his child, born in November, according to court records obtained by STAT. Denner is in the middle of a protracted divorce from his wife of nearly 25 years, with whom he has two teenage sons — a bitter legal fight in which his extramarital relationship with Langer is a contentious issue, according to the records.

Biogen spokesperson Jack Cox said the company knew about the relationship between Denner and Langer. He also said that Denner recommended Langer to Biogen’s board — he said he incorrectly stated at first that Denner nominated her — but declined to comment on the company’s vetting process and whether it planned to disclose the relationship to shareholders before they vote on Langer’s candidacy later this month. Biogen also omitted mention of the relationship from Langer’s biography in a Securities and Exchange Commission filing Tuesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Beyond aggravation: Constipation is an American epidemic

WSS

Bird flu makes raw milk dangerous to consume, mouse study finds

Vertex non

Some medical students still think black patients feel less pain

Achieving telehealth equity for people with hearing loss

Reconstructing family trees of blood cells may help predict disease

Why we need mandatory labeling of GMO products

entertainment

entertainment

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Heart attack and stroke risk calculators need revising

Zyn nicotine pouches become unlikely player in latest culture war

23andMe had bad news about my health. I wish a person had delivered it

Biogen walks away from Aduhelm, years after polarizing approval

Affirmative action in medical school literally saved lives

Medicare Advantage insurers face 0.2% cut to 2025 payments

Medicare proposal to cover medical devices draws a mixed reaction

Protect nursing home residents from future pandemics

focus

Decentralized clinical trials need collaboration to achieve wider use

Stroke rates rising, especially in working

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Humana’s losses in Medicare Advantage tank its stock

Reconstructing family trees of blood cells may help predict disease

How generative AI ratchets up security threats for health systems

leisure time

entertainment

entertainment

focus